NA Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

North America Kidney Cancer Diagnostics Market is projected to register a CAGR of 6.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

North America Kidney Cancer Diagnostics Market, By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stages (Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, and Non-Clear Cell Renal Cell Carcinoma), Product (Platform-Based Products, Instrument based products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, and Mexico), Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the kidney cancer diagnostics market are:

Rising healthcare expenditure for better health services

Increase in diagnostic procedure for kidney cancer

Growing prevalence of kidney cancer

Market Players

Some of the key market players for North America kidney cancer diagnostics market are listed below:

Ambry Genetics

BluePrint Oy.

Canon Medical Systems Corporation

CD Genomics

CENTOGENE N.V.

Creative Diagnostics

FUJIFILM Corporation

GeneDx, LLC

GenPath

Grail

Illumina, Inc.

Invitae Corporation

Koninklijke Philips N.V.

Laboratory Corporation of America Holdings

Myriad Genetics, Inc.

Qiagen

Seimens Healthcare GmbH

Thermo Fisher Scientific

1 INTRODUCTION 84

1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET 84
1.4 CURRENCY AND PRICING 86
1.5 LIMITATIONS 87
1.6 MARKETS COVERED 87

2 MARKET SEGMENTATION 91

2.1 MARKETS COVERED 91
2.2 GEOGRAPHICAL SCOPE 92
2.3 YEARS CONSIDERED FOR THE STUDY 93
2.4 DBMR TRIPOD DATA VALIDATION MODEL 94
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.6 MULTIVARIATE MODELLING 98
2.7 MARKET APPLICATION COVERAGE GRID 99
2.8 TEST TYPE LIFELINE CURVE 100
2.9 DBMR MARKET POSITION GRID 101
2.10 VENDOR SHARE ANALYSIS 102
2.11 SECONDARY SOURCES 103
2.12 ASSUMPTIONS 103

3 EXECUTIVE SUMMARY 104

4 PREMIUM INSIGHTS 107

4.1 PESTEL ANALYSIS 108
4.2 PORTER'S 5 FORCES 109
4.3 EPIDEMIOLOGY 110
- 4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 111
- 4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 111

5 INDUSTRY INSIGHTS 112

6 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 114

7 MARKET OVERVIEW 117

7.1 DRIVERS 119
- 7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 119
- 7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 121
- 7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 122
- 7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 122
7.2 RESTRAINTS 123
- 7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 123
- 7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 124
7.3 OPPORTUNITIES 124
- 7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 124
- 7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 125
- 7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 125
- 7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 126
7.4 CHALLENGES 126
- 7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 126
- 7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 127

8 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 128

8.1 OVERVIEW 129
8.2 IMAGING 133
- 8.2.1 COMPUTED TOMOGRAPHY 134
- 8.2.2 ULTRASOUND 134
- 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 134
- 8.2.4 ANGIOGRAPHY 134
- 8.2.5 X-RAY 134
- 8.2.6 OTHERS 134
8.3 BLOOD TEST 134
8.4 BIOPSY 135
- 8.4.1 FINE NEEDLE ASPIRATION 136
- 8.4.2 NEEDLE CORE BIOPSY 136
8.5 BIOMARKER TEST 136
- 8.5.1 AQUAPORIN 1 (AQP1) 138
- 8.5.2 PERILIPIN (PLIN2) 138
- 8.5.3 N-METHYLTRANSFERASE (NMNT) 138
- 8.5.4 L-PLASTIN (LCP-1) 138
- 8.5.5 NM23A 138
8.6 GENETIC TEST 138
8.7 OTHERS 139

9 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 141

9.1 OVERVIEW 142
9.2 STAGE I 145
9.3 STAGE II 145
9.4 STAGE III 146
9.5 STAGE IV 147

10 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 148

10.1 OVERVIEW 149
10.2 RENAL CELL CARCINOMA 153
- 10.2.1 IMAGING 154
- 10.2.2 BLOOD TEST 154
- 10.2.3 BIOPSY 154
- 10.2.4 BIOMARKER TEST 154
- 10.2.5 GENETIC TEST 154
- 10.2.6 OTHERS 154
10.3 CLEAR CELL RENAL CELL CARCINOMA 154
- 10.3.1 IMAGING 156
- 10.3.2 BLOOD TEST 156
- 10.3.3 BIOPSY 156
- 10.3.4 BIOMARKER TEST 156
- 10.3.5 GENETIC TEST 156
- 10.3.6 OTHERS 156
10.4 NON CLEAR CELL RENAL CELL CARCINOMA 156
- 10.4.1 PAPILLARY RENAL CELL CARCINOMA 157
  - 10.4.1.1 IMAGING 158
  - 10.4.1.2 BLOOD TEST 158
  - 10.4.1.3 BIOPSY 158
  - 10.4.1.4 BIOMARKER TEST 158
  - 10.4.1.5 GENETIC TEST 158
  - 10.4.1.6 OTHERS 158
- 10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 158
  - 10.4.2.1 IMAGING 159
  - 10.4.2.2 BLOOD TEST 159
  - 10.4.2.3 BIOPSY 159
  - 10.4.2.4 BIOMARKER TEST 159
  - 10.4.2.5 GENETIC TEST 159
  - 10.4.2.6 OTHERS 159

11 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 160

11.1 OVERVIEW 161
11.2 INSTRUMENT BASED PRODUCTS 165
- 11.2.1 IMAGING 166
- 11.2.2 BIOPSY 166
11.3 PLATFORM BASED PRODUCTS 166
- 11.3.1 NEXT GENERATION SEQUENCING 168
- 11.3.2 MICROARRAYS 168
- 11.3.3 PCR 169
- 11.3.4 OTHERS 169
11.4 KITS AND REAGENTS 169
- 11.4.1 RENAL CANCER PANELS 171
- 11.4.2 RENAL CANCER ANTIBODIES 171
11.5 OTHER CONSUMABLES 171

12 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 172

12.1 OVERVIEW 173
12.2 FLUORESCENT IN SITU HYBRIDIZATION 176
12.3 NEXT GENERATION SEQUENCING 176
12.4 FLUORIMMUNOASSAY 177
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 178
12.6 IMMUNOHISTOCHEMICAL 179
12.7 OTHERS 179

13 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 181

13.1 OVERVIEW 182
13.2 SCREENING 185
- 13.2.1 INSTRUMENT BASED PRODUCTS 186
- 13.2.2 PLATFORM BASED PRODUCTS 186
- 13.2.3 KITS AND REAGENTS 186
- 13.2.4 OTHER CONSUMABLES 186
13.3 DIAGNOSTIC AND PREDICTIVE 186
- 13.3.1 INSTRUMENT BASED PRODUCTS 187
- 13.3.2 PLATFORM BASED PRODUCTS 187
- 13.3.3 KITS AND REAGENTS 187
- 13.3.4 OTHER CONSUMABLES 187
13.4 PROGNOSTIC 188
- 13.4.1 INSTRUMENT BASED PRODUCTS 189
- 13.4.2 PLATFORM BASED PRODUCTS 189
- 13.4.3 KITS AND REAGENTS 189
- 13.4.4 OTHER CONSUMABLES 189
13.5 RESEARCH 189
- 13.5.1 INSTRUMENT BASED PRODUCTS 190
- 13.5.2 PLATFORM BASED PRODUCTS 190
- 13.5.3 KITS AND REAGENTS 190
- 13.5.4 OTHER CONSUMABLES 191

14 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 192

14.1 OVERVIEW 193
14.2 HOSPITALS 196
14.3 DIAGNOSTIC CENTERS 196
14.4 CANCER RESEARCH CENTERS 197
14.5 ACADEMIC INSTITUTES 198
14.6 AMBULATORY SURGICAL CENTERS 198
14.7 OTHERS 199

15 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 200

15.1 OVERVIEW 201
15.2 DIRECT TENDER 204
15.3 RETAIL SALES 204
15.4 OTHERS 205

16 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 206

16.1 NORTH AMERICA 207
- 16.1.1 U.S. 221
- 16.1.2 CANADA 230
- 16.1.3 MEXICO 239

17 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 248

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 248

18 SWOT ANALYSIS 249

19 COMPANY PROFILE 250

19.1 CANON MEDICAL SYSTEMS CORPORATION 250
- 19.1.1 COMPANY SNAPSHOT 250
- 19.1.2 REVENUE ANALYSIS 250
- 19.1.3 COMPANY PROFILE 251
- 19.1.4 PRODUCT PORTFOLIO 251
- 19.1.5 RECENT DEVELOPMENT 251
19.2 KONINKLIJKE PHILIPS N.V. 252
- 19.2.1 COMPANY SNAPSHOT 252
- 19.2.2 REVENUE ANALYSIS 252
- 19.2.3 COMPANY PROFILE 253
- 19.2.4 PRODUCT PORTFOLIO 253
- 19.2.5 RECENT DEVELOPMENTS 254
19.3 GENERAL ELECTRIC COMPANY 255
- 19.3.1 COMPANY SNAPSHOT 255
- 19.3.2 REVENUE ANALYSIS 255
- 19.3.3 COMPANY PROFILE 256
- 19.3.4 PRODUCT PORTFOLIO 256
- 19.3.5 RECENT DEVELOPMENTS 257
19.4 SIEMENS HEALTHCARE GMBH 258
- 19.4.1 COMPANY SNAPSHOT 258
- 19.4.2 REVENUE ANALYSIS 258
- 19.4.3 COMPANY PROFILE 259
- 19.4.4 PRODUCT PORTFOLIO 259
- 19.4.5 RECENT DEVELOPMENT 260
19.5 GRAIL 261
- 19.5.1 COMPANY SNAPSHOT 261
- 19.5.2 PRODUCT PORTFOLIO 261
- 19.5.3 RECENT DEVELOPMENTS 261
19.6 AMBRY GENETICS 263
- 19.6.1 COMPANY SNAPSHOT 263
- 19.6.2 PRODUCT PORTFOLIO 263
- 19.6.3 RECENT DEVELOPMENT 263
19.7 BIOVENDOR R&D 264
- 19.7.1 COMPANY SNAPSHOT 264
- 19.7.2 PRODUCT PORTFOLIO 264
- 19.7.3 RECENT DEVELOPMENT 264
19.8 BLUEPRINT GENETICS OY. 265
- 19.8.1 COMPANY SNAPSHOT 265
- 19.8.2 PRODUCT PORTFOLIO 265
- 19.8.3 RECENT DEVELOPMENT 265
19.9 CD GENOMICS 266
- 19.9.1 COMPANY SNAPSHOT 266
- 19.9.2 PRODUCT PORTFOLIO 266
- 19.9.3 RECENT DEVELOPMENT 266
19.10 CENTOGENE N.V. 267
- 19.10.1 COMPANY SNAPSHOT 267
- 19.10.2 REVENUE ANALYSIS 267
- 19.10.3 PRODUCT PORTFOLIO 268
- 19.10.4 RECENT DEVELOPMENT 268
19.11 CREATIVE DIAGNOSTICS 269
- 19.11.1 COMPANY SNAPSHOT 269
- 19.11.2 PRODUCT PORTFOLIO 269
- 19.11.3 RECENT DEVELOPMENT 269
19.12 FUJIFILM CORPORATION 270
- 19.12.1 COMPANY SNAPSHOT 270
- 19.12.2 REVENUE ANALYSIS 270
- 19.12.3 PRODUCT PORTFOLIO 271
- 19.12.4 RECENT DEVELOPMENTS 271
19.13 GENEDX, LLC 272
- 19.13.1 COMPANY SNAPSHOT 272
- 19.13.2 REVENUE ANALYSIS 272
- 19.13.3 PRODUCT PORTFOLIO 273
- 19.13.4 RECENT DEVELOPMENT 273
19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY 274
- 19.14.1 COMPANY SNAPSHOT 274
- 19.14.2 PRODUCT PORTFOLIO 274
- 19.14.3 RECENT DEVELOPMENT 274
19.15 ILLUMINA, INC. 275
- 19.15.1 COMPANY SNAPSHOT 275
- 19.15.2 REVENUE ANALYSIS 275
- 19.15.3 PRODUCT PORTFOLIO 276
- 19.15.4 RECENT DEVELOPMENT 276

19.16 INVITAE CORPORATION 277
- 19.16.1 COMPANY SNAPSHOT 277
- 19.16.2 REVENUE ANALYSIS 277
- 19.16.3 PRODUCT PORTFOLIO 278
- 19.16.4 RECENT DEVELOPMENT 278
19.17 LABORATORY CORPORATION OF AMERICA HOLDINGS 279
- 19.17.1 COMPANY SNAPSHOT 279
- 19.17.2 REVENUE ANALYSIS 279
- 19.17.3 PRODUCT PORTFOLIO 280
- 19.17.4 RECENT DEVELOPMENTS 280
19.18 MYRIAD GENETICS, INC. 281
- 19.18.1 COMPANY SNAPSHOT 281
- 19.18.2 REVENUE ANALYSIS 281
- 19.18.3 PRODUCT PORTFOLIO 282
- 19.18.4 RECENT DEVELOPMENT 282
19.19 THERMO FISHER SCIENTIFIC INC. 283
- 19.19.1 COMPANY SNAPSHOT 283
- 19.19.2 REVENUE ANALYSIS 283
- 19.19.3 PRODUCT PORTFOLIO 284
- 19.19.4 RECENT DEVELOPMENT 284
19.20 QIAGEN 285
- 19.20.1 COMPANY SNAPSHOT 285
- 19.20.2 REVENUE ANALYSIS 285
- 19.20.3 PRODUCT PORTFOLIO 286
- 19.20.4 RECENT DEVELOPMENT 286

20 QUESTIONNAIRE 287

21 RELATED REPORTS 291

LIST OF TABLES

TABLE 1 ESTIMATED NEW CANCER CASES AND DEATHS 59
TABLE 2 APPROVED DIAGNOSTICS OF KIDNEY CANCER 61
TABLE 3 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 72
TABLE 4 NORTH AMERICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 5 NORTH AMERICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 74
TABLE 6 NORTH AMERICA BLOOD TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 7 NORTH AMERICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 8 NORTH AMERICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 76
TABLE 9 NORTH AMERICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 10 NORTH AMERICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 78
TABLE 11 NORTH AMERICA GENETIC TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 12 NORTH AMERICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 13 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 84
TABLE 14 NORTH AMERICA STAGE I IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 15 NORTH AMERICA STAGE II IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 16 NORTH AMERICA STAGE III IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 17 NORTH AMERICA STAGE IV IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 18 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 92
TABLE 19 NORTH AMERICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 93
TABLE 20 NORTH AMERICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 94
TABLE 21 NORTH AMERICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
TABLE 22 NORTH AMERICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 95
TABLE 23 NORTH AMERICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 24 NORTH AMERICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 97
TABLE 25 NORTH AMERICA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
TABLE 26 NORTH AMERICA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
TABLE 27 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 104
TABLE 28 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 29 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 106
TABLE 30 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 106
TABLE 31 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 106
TABLE 32 NORTH AMERICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 107
TABLE 33 NORTH AMERICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 108
TABLE 34 NORTH AMERICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 108
TABLE 35 NORTH AMERICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 108
TABLE 36 NORTH AMERICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 37 NORTH AMERICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 110
TABLE 38 NORTH AMERICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 110
TABLE 39 NORTH AMERICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 110
TABLE 40 NORTH AMERICA OTHER CONSUMABLES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
TABLE 41 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 115
TABLE 42 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
TABLE 43 NORTH AMERICA NEXT GENERATION SEQUENCING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 117
TABLE 44 NORTH AMERICA FLUORIMMUNOASSAY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
TABLE 45 NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
TABLE 46 NORTH AMERICA IMMUNOHISTOCHEMICAL IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
TABLE 47 NORTH AMERICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
TABLE 48 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 124
TABLE 49 NORTH AMERICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 125
TABLE 50 NORTH AMERICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 125
TABLE 51 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
TABLE 52 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 127
TABLE 53 NORTH AMERICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
TABLE 54 NORTH AMERICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 128
TABLE 55 NORTH AMERICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 130
TABLE 56 NORTH AMERICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 130
TABLE 57 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 135
TABLE 58 NORTH AMERICA HOSPITALS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 136
TABLE 59 NORTH AMERICA DIAGNOSTIC CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
TABLE 60 NORTH AMERICA CANCER RESEARCH CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
TABLE 61 NORTH AMERICA ACADEMIC INSTITUTES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 138
TABLE 62 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 139
TABLE 63 NORTH AMERICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 139
TABLE 64 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 143
TABLE 65 NORTH AMERICA DIRECT TENDER IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 144
TABLE 66 NORTH AMERICA RETAIL SALES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 145
TABLE 67 NORTH AMERICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 145
TABLE 68 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 152
TABLE 69 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
TABLE 70 NORTH AMERICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
TABLE 71 NORTH AMERICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 153
TABLE 72 NORTH AMERICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 153
TABLE 73 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 153
TABLE 74 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 153
TABLE 75 NORTH AMERICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
TABLE 76 NORTH AMERICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
TABLE 77 NORTH AMERICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 154
TABLE 78 NORTH AMERICA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 79 NORTH AMERICA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 80 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 155
TABLE 81 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 156
TABLE 82 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 156
TABLE 83 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 156
TABLE 84 NORTH AMERICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 156
TABLE 85 NORTH AMERICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 157
TABLE 86 NORTH AMERICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 157
TABLE 87 NORTH AMERICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 157
TABLE 88 NORTH AMERICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 158
TABLE 89 NORTH AMERICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 158
TABLE 90 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 158
TABLE 91 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 158
TABLE 92 NORTH AMERICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 159
TABLE 93 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 159
TABLE 94 NORTH AMERICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 159
TABLE 95 NORTH AMERICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 160
TABLE 96 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 160
TABLE 97 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 160
TABLE 98 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 99 U.S. IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 100 U.S. BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 101 U.S. BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 102 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 162
TABLE 103 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 162
TABLE 104 U.S. RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
TABLE 105 U.S. CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
TABLE 106 U.S. NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 163
TABLE 107 U.S. PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
TABLE 108 U.S. CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
TABLE 109 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
TABLE 110 U.S. INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 111 U.S. INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 165
TABLE 112 U.S. INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 165
TABLE 113 U.S. PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 114 U.S. PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 166
TABLE 115 U.S. PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 166
TABLE 116 U.S. KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
TABLE 117 U.S. KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 166
TABLE 118 U.S. KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 166
TABLE 119 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 167
TABLE 120 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 167
TABLE 121 U.S. SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
TABLE 122 U.S. DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 168
TABLE 123 U.S. PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 168
TABLE 124 U.S. RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 168
TABLE 125 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 169
TABLE 126 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 169
TABLE 127 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 128 CANADA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 129 CANADA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 130 CANADA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
TABLE 131 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 171
TABLE 132 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 171
TABLE 133 CANADA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 172
TABLE 134 CANADA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 172
TABLE 135 CANADA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 172
TABLE 136 CANADA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 173
TABLE 137 CANADA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 173
TABLE 138 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
TABLE 139 CANADA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 174
TABLE 140 CANADA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 174
TABLE 141 CANADA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 174
TABLE 142 CANADA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 174
TABLE 143 CANADA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 175
TABLE 144 CANADA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 175
TABLE 145 CANADA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 175
TABLE 146 CANADA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 175
TABLE 147 CANADA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 175
TABLE 148 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 176
TABLE 149 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 176
TABLE 150 CANADA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 176
TABLE 151 CANADA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 177
TABLE 152 CANADA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 177
TABLE 153 CANADA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 177
TABLE 154 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 178
TABLE 155 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 178
TABLE 156 MEXICO KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 179
TABLE 157 MEXICO IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 179
TABLE 158 MEXICO BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 179
TABLE 159 MEXICO BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 180
TABLE 160 MEXICO KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 180
TABLE 161 MEXICO KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 180
TABLE 162 MEXICO RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 181
TABLE 163 MEXICO CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 181

LIST OF FIGURES

FIGURE 1 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION 30
FIGURE 2 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 33
FIGURE 3 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 34
FIGURE 4 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 35
FIGURE 5 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 35
FIGURE 6 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 36
FIGURE 7 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 38
FIGURE 8 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 40
FIGURE 9 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 41
FIGURE 10 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION 45
FIGURE 11 GROWING AWARENESS OF KIDNEY CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030 46
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET IN 2023 & 2030 46
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET 57
FIGURE 14 KIDNEY CANCER INCIDENCE, BOTH SEXES, BY REGION (2020) 59
FIGURE 15 KIDNEY CANCER MORTALITY, BOTH SEXES, BY REGION (2020) 59
FIGURE 16 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022 69
FIGURE 17 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION) 70
FIGURE 18 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030) 70
FIGURE 19 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE 71
FIGURE 20 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE , 2022 81
FIGURE 21 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, 2023-2030 (USD MILLION) 82
FIGURE 22 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, CAGR (2023-2030) 82
FIGURE 23 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, LIFELINE CURVE 83
FIGURE 24 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2022 89
FIGURE 25 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2023-2030 (USD MILLION) 90
FIGURE 26 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, CAGR (2023-2030) 90
FIGURE 27 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, LIFELINE CURVE 91
FIGURE 28 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2022 101
FIGURE 29 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2023-2030 (USD MILLION) 102
FIGURE 30 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, CAGR (2023-2030) 102
FIGURE 31 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, LIFELINE CURVE 103
FIGURE 32 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022 112
FIGURE 33 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2023-2030 (USD MILLION) 113
FIGURE 34 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2023-2030) 113
FIGURE 35 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE 114
FIGURE 36 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2022 121
FIGURE 37 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2023-2030 (USD MILLION) 122
FIGURE 38 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, CAGR (2023-2030) 122
FIGURE 39 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, LIFELINE CURVE 123
FIGURE 40 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2022 132
FIGURE 41 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 133
FIGURE 42 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 133
FIGURE 43 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 134
FIGURE 44 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 140
FIGURE 45 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 141
FIGURE 46 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 141
FIGURE 47 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 142
FIGURE 48 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 147
FIGURE 49 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 149
FIGURE 50 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 149
FIGURE 51 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 150
FIGURE 52 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 150
FIGURE 53 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 187